After taking a hard look at the data, Novartis punts Aduro’s STING drug — the latest in a long line of setbacks
Things keep getting worse at the beleaguered Aduro.
Ten months after CEO Stephen Isaacs was forced to restructure and downsize the staff after a series of setbacks, Novartis is dumping Aduro’s lead surviving drug after concluding from the clinical data that there was no reason to push forward.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,600+ biopharma pros reading Endpoints daily — and it's free.